Global Alzheimer’s Platform Foundation Announces Strategic Collaboration with Eli Lilly and Company for the Transformative Bio-Hermes-002 Study Washington D.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This...

Collaborative effort to conduct a study aimed at improving the diagnosis of Alzheimer’s and related dementias for everyone Washington D.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome the initial strategic partners in the Bio-Hermes-002 study. These...

UNLV and Innovative Clinical Research Organization Collaborating to Bring Next Generation Research to Las Vegas Washington D.C., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Today, Global Alzheimer’s Platform Foundation® (GAP) and the University of Nevada, Las Vegas (UNLV), announced a memorandum of understanding (MOU)...

Dementia Mission Competition Selects Four Companies For Innovative Alzheimer’s Biomarker Study Washington D.C., July 10, 2024 (GLOBE NEWSWIRE) -- With groundbreaking creativity and breathtaking speed, this phase 3 competition, funded by Innovate UK, the UK’s innovation agency, is supporting...

Promising Pathways to Simplified Alzheimer's Diagnosis Unveiled in Groundbreaking Study Washington D.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Washington D.C., Feb. 28, 2024- The Global Alzheimer’s Platform Foundation®, (GAP) is releasing the first results from the Bio-Hermes-001 Study....